Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04545047 · ClinicalTrials.gov registry record
Observational Study of Convalescent Plasma for Treatment of Veterans With COVID-19
A clinical trial, sponsored by VA Office of Research and Development.
- Completed
- Registry status
- 5,044
- Enrollment target
NCT04545047: Completed study, sponsored by VA Office of Research and Development.
NCT04545047 is a clinical trial that has completed, run by VA Office of Research and Development. The registered enrollment target is 5,044 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04545047 has completed, sponsored by VA Office of Research and Development.
- COMPLETED
- Registry status
- 5,044 participants
- Enrollment target
Study Summary
The purpose of this study is to assess whether convalescent plasma therapy is associated with reduced 30-day all-cause mortality in a population of Veteran inpatients with non-severe coronavirus disease 2019 (COVID-19).
Interventions
- BIOLOGICAL COVID-19 convalescent plasma
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,044 participants |
| Start Date | 2020-05-01 |
| Est. Completion | 2021-10-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04545047
The ClinicalTrials.gov registry entry for NCT04545047 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 5,044 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which COVID-19 convalescent plasma is the first listed.
NCT04545047 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04545047 about?
NCT04545047 is a clinical study titled "Observational Study of Convalescent Plasma for Treatment of Veterans With COVID-19". The purpose of this study is to assess whether convalescent plasma therapy is associated with reduced 30-day all-cause mortality in a population of Veteran inpatients with non-severe coronavirus disease 2019 (COVID-19).
What is the current status of trial NCT04545047?
This trial is currently completed. The enrollment target is 5,044 participants. The study started on 2020-05-01. Estimated completion is 2021-10-01.
What interventions are being tested in trial NCT04545047?
The interventions under investigation include: COVID-19 convalescent plasma (BIOLOGICAL).
Who is sponsoring clinical trial NCT04545047?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.